Fast-acting APL-130277 is a thin film sublingual formulation of apomorphine, which is designed for use in the rescue of Parkinson’s patients from "off" episodes in which the patients have impaired movement or speaking capabilities.
Cynapsus president and chief executive officer Anthony Giovinazzo said the issuance of the patent for APL-130277 will enable the company to launch the product in 2015.
"We are very pleased that our intellectual property estate on our sublingual apomorphine project is advancing nicely alongside scientific, clinical and other business developments," Giovinazzo added.